NCT01154738

Brief Summary

The objective is to evaluate the sparing effect of Lidocaine on doses of propofol and remifentanil.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jan 2011

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 25, 2010

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 1, 2010

Completed
6 months until next milestone

Study Start

First participant enrolled

January 1, 2011

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

November 3, 2016

Status Verified

November 1, 2016

Enrollment Period

4 years

First QC Date

June 25, 2010

Last Update Submit

November 2, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • administered dose of propofol during maintenance of anesthesia

    day 1

Secondary Outcomes (8)

  • administered dose of propofol during induction of anesthesia

    day 1

  • administered doses of remifentanil during induction and maintenance of anesthesia

    day 1

  • delay (measured as minutes) between the end of propofol and remifentanil administration and the recovery from anesthesia

    day 1

  • hemodynamic abnormalities requiring treatment

    day 1

  • % of time with a BIS index between 40 and 60

    day 1

  • +3 more secondary outcomes

Study Arms (2)

Lidocaine

EXPERIMENTAL

Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine

Drug: Lidocaine

Placebo

PLACEBO COMPARATOR

patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo

Drug: Placebo

Interventions

bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia. start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine

Lidocaine

NaCl 9/00 (same volume as in the lidocaine group) start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients ASA 1, 2 or 3 scheduled for a general anesthesia surgical procedure (abdominal surgery, urology, ENT major procedure) lasting between 1 and 3 hours

You may not qualify if:

  • age under 18 years
  • simultaneous general and loco-regional anesthesia
  • allergy to NSAID
  • treatment with verapamil, ketamine or gabapentin
  • patients receiving an opioid preoperatively
  • severe hepatic insufficiency
  • contra-indication to lidocaine
  • contra-indication to propofol or to remifentanil
  • history of central nervous system disease
  • patients receiving a psychotropic treatment
  • patients with a pace-maker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Tenon

Paris, 75020, France

Location

MeSH Terms

Interventions

Lidocaine

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Marc Fischler, MD

    Hôpital Foch

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2010

First Posted

July 1, 2010

Study Start

January 1, 2011

Primary Completion

January 1, 2015

Study Completion

January 1, 2015

Last Updated

November 3, 2016

Record last verified: 2016-11

Locations